Maha Mohammad Eissa

Maha Mohammad Eissa

Auto-generated profile, based on publicly available information

Maha Mohammad Eissa

Alexandria University

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MEMaha M. Eissa
Maha M. Eissa
RERiham M. El-Moslemany
Riham M. El-Moslemany
ARAlyaa A. Ramadan
Alyaa A. Ramadan
EAEglal I. Amer
Eglal I. Amer
MEMervat Z. El-Azzouni
Mervat Z. El-Azzouni
LELabiba El-Khordagui
Labiba El-Khordagui
Miltefosine (MFS) is an alkylphosphocholine used for the local treatment of cutaneous metastases of breast cancer and oral therapy of visceral leishmaniasis. Recently, the drug was reported in in vitro and preclinical studies to exert significant activity against different developmental stages of schistosomiasis mansoni, a widespread chronic neglected tropical disease (NTD). This justified MFS repurposing as a potential antischistosomal drug. However, five consecutive daily 20 mg/kg doses were needed for the treatment of schistosomiasis mansoni in mice. The present study aims at enhancing MFS efficacy to allow for a single 20mg/kg oral dose therapy using a nanotechnological approach based on lipid nanocapsules (LNCs) as oral nanovectors. MFS was incorporated in LNCs both as membrane-active structural alkylphospholipid component and active antischistosomal agent. MFS-LNC formulations showed high entrapment efficiency (EE%), good colloidal properties, sustained release pattern and physical stability. Further, LNCs generally decreased MFS-induced erythrocyte hemolytic activity used as surrogate indicator of membrane activity. While MFS-free LNCs exerted no antischistosomal effect, statistically significant enhancement was observed with all MFS-LNC formulations. A maximum effect was achieved with MFS-LNCs incorporating CTAB as positive charge imparting agent or oleic acid as membrane permeabilizer. Reduction of worm load, ameliorated liver pathology and extensive damage of the worm tegument provided evidence for formulation-related efficacy enhancement. Non-compartmental analysis of pharmacokinetic data obtained in rats indicated independence of antischistosomal activity on systemic drug exposure, suggesting possible gut uptake of the stable LNCs and targeting of the fluke tegument which was verified by SEM. The study findings put forward MFS-LNCs as unique oral nanovectors combining the bioactivity of MFS and biopharmaceutical advantages of LNCs, allowing targeting via the oral route. From a clinical point of view, data suggest MFS-LNCs as a potential single dose oral nanomedicine for enhanced therapy of schistosomiasis mansoni and possibly other diseases.

1 February 2011 in International Journal for Parasitology
Verified
Journal Article
Closed access
MEMaha M. Eissa
Maha M. Eissa
MEMervat Z. El-Azzouni
Mervat Z. El-Azzouni
EAEglal I. Amer
Eglal I. Amer
NBNahed M. Baddour
Nahed M. Baddour

1 December 1995 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
MYMagda Y. M. Youssef
Magda Y. M. Youssef
HSHayam A. H. Sadaka
Hayam A. H. Sadaka
MEMaha M. Eissa
Maha M. Eissa
AEAli F. El-Ariny
Ali F. El-Ariny
Ivermectin is used in veterinary practice against many ectoparasites and endoparasites and is the drug of choice for treatment of human onchocerciasis. This study was carried out to investigate the effect of topical application of this drug against human ectoparasites (Sarcoptes scabiei and Pediculus humanus capitis). Ivermectin was found to have a curative effect on head lice after a single topical application. In patients with scabies, the drug was also found to be effective after a single application. However, in 50% of the cases, another application was needed five days later.

1 November 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MEMaha M. Eissa
Maha M. Eissa
DMDalia K. Mostafa
Dalia K. Mostafa
AGAmany A. Ghazy
Amany A. Ghazy
MAMervat Z. El Azzouni
Mervat Z. El Azzouni
LBLaila M. Boulos
Laila M. Boulos
LYLayla K. Younis
Layla K. Younis
A growing body of evidence supports the concept of helminths therapy in a variety of autoimmune diseases. Here, we aimed to investigate the protective effects of autoclaved Schistosoma mansoni antigen (ASMA) and Trichinella spiralis antigen (ATSA) on the clinical and immunopathological features of rheumatoid arthritis (RA). Adjuvant arthritis was induced by subcutaneous and intradermal injections of complete Freund’s adjuvant into the plantar surface of the right hind paw and the root of the tail, respectively. Rats were randomly assigned to serve as normal control, untreated arthritis, ASMA or ATSA-treated arthritis groups. Antigens were given by intradermal injection in two doses, two weeks apart. The development, progression of arthritic features, and the impact on animals’ gait and body weight were followed up for 4 weeks. The associated changes in serum cytokines (IL-17, IFN-γ and IL-10), joints’ histopathology and immunohistochemistry of Foxp3+ T regulatory cells (Tregs) were evaluated at the end of the study. Treatment with either ASMA or ATSA attenuated the progression of clinical features of polyarthritis, improved gait and body weight gain, reduced the elevated serum IL-17 and further increased both IFN-γ and IL-10. Histopathologically, this was associated with a remarkable regression of paws’ inflammation that was limited only to the subcutaneous tissue, and a significant increase in the number of Foxp 3+ cells versus the untreated arthritis group. In conclusion, both Schistosoma mansoni and Trichinella spiralis derived antigens exerted protective effect against adjuvant arthritis with better effect achieved by ASMA treatment. This anti-arthritic activity is attributed to upregulation of the Foxp3+ Tregs, with subsequent favorable modulation of both pro- and anti-inflammatory cytokines. The use of autoclaved parasitic antigens excludes the deleterious effects of imposing helminthic infection by using live parasites, which may pave the way to a new therapeutic modality in treating RA.

11 May 2011 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
MEMaha M Eissa
Maha M Eissa
SBSamia El Bardicy
Samia El Bardicy
MTMenerva Tadros
Menerva Tadros
Miltefosine, which is the first oral drug licensed for the treatment of leishmaniasis, was recently reported to be a promising lead compound for the synthesis of novel antischistosomal derivatives with potent activity in vivo against different developmental stages of Schistosoma mansoni. In this paper an in vitro study was carried out to investigate whether it has a biocidal activity against the aquatic stages of Schistosoma mansoni and its snail intermediate host, Biomphalaria alexandrina , thus being also a molluscicide. Additionally, to see whether miltefosine can have a broad spectrum antischistosomal activity, a similar in vitro study was carried out on the adult stage of Schistosoma haematobium, the second major human species, its larval stages and snail intermediate host, Bulinus truncutes. This was checked by scanning electron microscopy.

1 August 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
RARokaya Amara
Rokaya Amara
ARalyaa ramadan
alyaa ramadan
RERiham M El-Moslemany
Riham M El-Moslemany
MEMaha M Eissa
Maha M Eissa
MEMervat Z El-Azzouni
Mervat Z El-Azzouni
LELabiba El-Khordagui
Labiba El-Khordagui
Purpose: Lipid nanocapsules (LNCs) have shown potential to increase the bioavailability and efficacy of orally administered drugs. However, their intestinal translocation to distal target sites and their implication in pharmacokinetic (PK)–pharmacodynamic (PD) relationships are yet to be elucidated. In this study, the effect of LNCs on the PD activity and pharmacokinetics of praziquantel (PZQ), the mainstay of schistosomiasis chemotherapy, was investigated. Materials and methods: The composition of LNCs was modified to increase PZQ payload and to enhance membrane permeability. PZQ–LNCs were characterized in vitro for colloidal properties, entrapment efficiency (EE%), and drug release. PD activity of the test formulations was assessed in Schistosoma mansoni-infected mice 7 days post-oral administration of a single 250 mg/kg oral dose. Pharmacokinetics of the test formulations and their stability in simulated gastrointestinal (GI) fluids were investigated to substantiate in vivo data. Results: PZQ–LNCs exhibited good pharmaceutical attributes in terms of size (46–62 nm), polydispersity index (0.01–0.08), EE% (>95%), and sustained release profiles. Results indicated significant efficacy enhancement by reduction in worm burden, amelioration of liver pathology, and extensive damage to the fluke suckers and tegument. This was partly explained by PK data determined in rats. In addition, oral targeting of the worms was supported by the stability of PZQ–LNCs in simulated GI fluids and scanning electron microscopy (SEM) visualization of nanostructures on the tegument of worms recovered from mesenteric/hepatic veins. Cytotoxicity data indicated tolerability of PZQ–LNCs. Conclusion: Data obtained provide evidence for the ability of oral LNCs to target distal postabsorption sites, leading to enhanced drug efficacy. From a practical standpoint, PZQ–LNCs could be suggested as a potential tolerable single lower dose oral nanomedicine for more effective PZQ mass chemotherapy.